This paper is only available as a PDF. To read, Please Download here.
Summary of Objectives
Inhalational drug delivery to treat PAH is attractive due to enhanced pulmonary specificity and reduced systemic adverse effects. LIQ861 is a dry powder formulation of Treprostinil (TRE) designed to enhance deep-lung delivery and achieve higher tolerated dose levels than current inhaled therapies. LIQ861’s uniform (1µm) particle size with a trefoil, pollen-like shape, enables QID delivery of TRE doses in a convenient, palm-sized, disposable dry powder inhaler (DPI). The primary objective of the INSPIRE study is the safety and tolerability of LIQ861 in subjects transitioning from stable doses of Tyvaso® or as combination therapy with ≤2 approved non-prostacyclin (PGI) oral PAH drugs. The secondary objective is to evaluate the comparative bioavailability (BA) of TRE between LIQ861 and Tyvaso®.
Target enrollment is 100 Functional Class (FC) II/III subjects with 18 subjects on Tyvaso® included in a BA sub-study comparing TRE exposure in a one-directional crossover. PGI-naïve subjects stable on ≤2 approved, non-PGI oral PAH therapies received LIQ861 at an initial dose of 25mcg QID, increasing in 25mcg increments weekly to tolerance and symptom relief. Subjects transitioning from Tyvaso® received LIQ861 at an initial dose comparable to their Tyvaso® dose, with titration in 25mcg QID increments to tolerance and symptom relief.
The primary endpoint is the incidence of treatment-emergent Adverse Events and Serious Adverse Events. Safety endpoints: • Changes from Baseline to Month 2 or Early Termination in clinical laboratory, physical exam findings, and vital signs. • Proportion of patients maintaining a stable clinical status from transition through Month 2. Stable clinical status defined as: 1) LIQ861 treatment through at least 2 months beyond transition from Tyvaso® and six-minute walk distance (6MWD) decrease no more than 10%, 2) no interruptions to treatment totaling more than 7 days prior to the end of Month 2, and 3) no treatment with any other PGI analogs or P`GI receptor agonists. Secondary endpoints: NYHA FC, N-terminal B-type natriuretic peptide and Quality of Life will be reported when available. Analysis for the Primary Endpoint and BA sub-study is expected to be completed in 2019.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal of Heart and Lung Transplantation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2019 Published by Elsevier Inc.